Drugs / ADSTEM Inj.
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02888704 | Jul 2016 → Dec 2017 | atopic eczema | EHL Bio Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04137562 | Dec 2019 → Jan 2023 overdue | atopic eczema | EHL Bio Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADSTEM Inj. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04137562 ↗ |
| Modality | Cell therapy | “autologous mesenchymal stem cells” NCT02888704 ↗ |
| Route | Intravenous | “intravenous injection” NCT02888704 ↗ |